Clinical Evaluation of Human Umbilical Cord Mesenchymal Stem Cell Transplantation After Angioplasty for Diabetic Foot

Qin, Hui; Zhu, Xiaomei; Zhang, B.; Zhou, Ling; Wang, W. Y.

doi:10.1055/s-0042-103684

Cited by 100 publications

(95 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with the present results, previous studies have indicated that MSCs therapies achieved therapeutic effect on diabetes or its complication [10,[12][13][14][15]. A phase I trial involving 8 patients, which investigated the therapeutic potentials of intra-arterial allogeneic BM-MSCs treatment for CLI, indicated that improvements of resting pain, ABI, and transcutaneous oxygen pressure were found after cell therapy [16].…”

Section: Discussionsupporting

confidence: 90%

Safety and Efficacy of Placenta-Derived Mesenchymal Stem Cell Treatment for Diabetic Patients with Critical Limb Ischemia: A Pilot Study

Wang

Zeng

Cai

et al. 2019

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Aim Diabetic foot has become the main cause of non-traumatic amputation. Stem cell therapy, especially mesenchymal stem cells (MSCs), holds a great promise as a therapy for diabetic foot with ischemia limb arterial disease. The aim of this pilot study is to evaluate the safety and efficacy of placenta-derived MSCs (P-MSCs) treatment for diabetic patients with critical limb ischemia (CLI). Methods Four eligible diabetic patients with CLI were consecutively enrolled in this pilot study. On the base of the standard-of-care treatment, these patients accepted P-MSCs treatment by intramuscular injection for successive 3 times at an interval of 4 weeks, and the safety and efficacy of placenta-derived MSCs (P-MSCs) treatment were evaluated. Results There were no serious adverse events during the period of P-MSCs injection and the 24-weeks follow-up period. The clinical ischemic features of patients were improved 24 weeks after P-MSCs treatment. The scores of resting pain and limb coldness significantly decreased, and pain-free walking distance significantly increased from baseline to 24 weeks after P-MSCs therapy. The resting ankle brachial index increased, but no statistically significant difference was found. The findings of magnetic resonance angiography showed the increase of collateral vessel formation in one patient, but there were no significant changes observed in the other patients. Conclusions The data in this pilot study indicated that multiple intramuscular P-MSCs injections may be a safe and effective alternative therapy for diabetic patients with CLI, and larger, placebo-controlled, perspective studies are needed to prove these results.

show abstract

Section: Discussionsupporting

confidence: 90%

Safety and Efficacy of Placenta-Derived Mesenchymal Stem Cell Treatment for Diabetic Patients with Critical Limb Ischemia: A Pilot Study

Wang

Zeng

Cai

et al. 2019

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…Following careful screening of titles and abstracts, 399 articles were excluded leaving 7 articles that fulfilled the predefined inclusion criteria and were included in the final analysis [20][21][22][23][24][25][26]. A total of 6 publications were full-text articles out the 7 studies [20,[22][23][24][25][26], whereas 1 publication was a meeting conference [21].…”

Section: Study Selectionmentioning

confidence: 99%

“…No significant change was noted with regard to the outcomes investigated, with the exception of the degree of heterogeneity in the TcPO2 group that was decreased following the removal of the study by Qin et al [20]. The funnel plot was not used to assess publication bias as it was deemed inappropriate, as recommended by the Cochrane handbook due to the small number of studies included [27].…”

Section: Sensitivity Analysis and Publication Biasmentioning

confidence: 99%

Efficiency of stem cell based therapy in the treatment of diabetic foot ulcer: a meta-analysis

Shu

Tang

et al. 2018

Endocr J

View full text Add to dashboard Cite

Abstract. Diabetic foot ulcer is a chronic, refractory, frequent complication in diabetic patient. Its treatment often requires multidisciplinary joint efforts, diverse strategies have been adopted to address this annoying issue, including stem cell-based therapy/acellular dermal matrix/negative pressure wound therapy etc. However, consensus has not been reached. To assess the current evidence regarding the efficiency and potential advantages of stem cell-based therapy compared with conventional standard treatment and/or placebo in the treatment of diabetic foot ulcer. A comprehensive search in PubMed, EmBase, Cochrane Central and Web of Science databases was conducted during December 2016 and a systematic review and metaanalysis of all relevant studies were performed. A total of 7 studies that involved 224 diabetic foot patients, classified as Wagner grades 1-5, were analyzed. The pooled results confirmed the benefits of using the stem cell treatment. Partial and/or complete healing were significantly higher in the stem cell group compared with the control group (77.4% vs. 31.9%; RR: 2.22; 95% CI, 1.65-2.98). Subgroup analysis on ABI and TCP02 also confirmed the results. The present meta-analysis indicates that stem cell-based therapy can enhance the healing of diabetic foot ulcers and is associated with lesser pain, lower amputation rate and improved prognosis compared with normal treatment. Well-designed randomized controlled trials are required in the future in order to confirm and update these findings.

show abstract

“…UC-MSCs have been reported as promising MSC sources for treating various diseases in humans, including heart failure [74], type 2 diabetes mellitus [75], ankylosing spondylitis [76], and angioplasty for diabetic feet [77].…”

Section: Discussionmentioning

confidence: 99%

Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study

Bich¹,

Thi²,

Chau³

et al. 2020

Stem Cell Res Ther

View full text Add to dashboard Cite

Introduction: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. COPD results from chronic inflammation of the lungs. Current treatments, including physical and chemical therapies, provide limited results. Stem cells, particularly mesenchymal stem cells (MSCs), are used to treat COPD. Here, we evaluated the safety and efficacy of umbilical cord-derived (UC)-MSCs for treating COPD. Methods: Twenty patients were enrolled, 9 at stage C and 11 at stage D per the Global Initiative for Obstructive Lung Disease (GOLD) classification. Patients were infused with 10 6 cells/kg of expanded allogeneic UC-MSCs. All patients were followed for 6 months after the first infusion. The treatment end-point included a comprehensive safety evaluation, pulmonary function testing (PFT), and quality-of-life indicators including questionnaires, the 6-min walk test (6MWT), and systemic inflammation assessments. All patients completed the full infusion and 6-month follow-up. Results: No infusion-related toxicities, deaths, or severe adverse events occurred that were deemed related to UC-MSC administration. The UC-MSC-transplanted patients showed a significantly reduced Modified Medical Research Council score, COPD assessment test, and number of exacerbations. However, the forced expiratory volume in 1 s, C-reactive protein, and 6MWT values were nonsignificantly reduced after treatment (1, 3, and 6 months) compared with those before the treatment. Conclusion: Systemic UC-MSC administration appears to be safe in patients with moderate-to-severe COPD, can significantly improve their quality of life, and provides a basis for subsequent cell therapy investigations.

show abstract

Clinical Evaluation of Human Umbilical Cord Mesenchymal Stem Cell Transplantation After Angioplasty for Diabetic Foot

Cited by 100 publications

References 16 publications

Safety and Efficacy of Placenta-Derived Mesenchymal Stem Cell Treatment for Diabetic Patients with Critical Limb Ischemia: A Pilot Study

Safety and Efficacy of Placenta-Derived Mesenchymal Stem Cell Treatment for Diabetic Patients with Critical Limb Ischemia: A Pilot Study

Efficiency of stem cell based therapy in the treatment of diabetic foot ulcer: a meta-analysis

Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study

Contact Info

Product

Resources

About